Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer’s disease

BackgroundAlzheimer’s Disease (AD) is a prevalent neurodegenerative disorder which involves a complex pathobiology driven by amyloid-beta (Aβ) and tau pathologies, among other factors. Aβ peptides are generated via β-secretase (BACE1) and γ-secretase cleavage of amyloid precursor protein (APP). Whil...

Full description

Bibliographic Details

Main Authors:	Lothar Lindemann, Julie Lambotte, Judith Rothe, Jürg Messer, Catherine Diener, Solen Pichereau, Carina Cantrill, Thomas Mueggler, Michael Honer, Jennifer Beck, Thomas Steinbrecher, Rosanna Tortelli, Irene Gerlach, Hasane Ratni, Rosa Maria Rodriguez Sarmiento, Karlheinz Baumann
Format:	Artigo
Language:	Inglês
Published:	Frontiers Media S.A. 2026-05-01
Series:	Frontiers in Pharmacology
Subjects:	Alzheimer’s disease amyloid beta disease-modifying therapy gamma secrease modulator gamma secretase GSM
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1783414/full
Tags:	Add Tag No Tags, Be the first to tag this record!